EDITORIAL COMMENT

Primary hyperoxaluria type 1: time for prime time?
Justine Bacchetta¹,²,³ and Kyle D. Wood⁴

¹Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Centre de Référence des Maladies Rénales Rares Néphrogones, Filières Maladies Rares ORKID et ERK-Net, CHU de Lyon, Bron, France, ²INSERM 1033, Research Unit, Université Claude Bernard Lyon 1, Lyon, France, ³Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France and ⁴Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA

Correspondence to: Justine Bacchetta; E-mail: justine.bacchetta@chu-lyon.fr

ABSTRACT

Oxalate crystals in the kidney were first described in 1925. Since then, many major milestones have been reached in the understanding of genetic primary hyperoxaluria(s). Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease due to a mutation in the AGXT gene, which encodes the hepatic peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), inducing excess oxalate production and further kidney stones, nephrocalcinosis and chronic kidney disease (CKD). Symptoms and age at diagnosis of PH1 vary dramatically, from the most severe infantile forms leading to end-stage kidney disease (ESKD) during the first months of life to the less severe adult forms with moderate CKD and recurrent kidney stones. In 2020, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved a therapy based on RNA interference (RNAi) that profoundly reduces endogenous oxalate synthesis and dramatically changes the treatment algorithm for patients with PH1.

The aim of this supplement of Clinical Kidney Journal includes contemporary reviews of the pathophysiology and genetics, (conventional) medical therapeutic management, urological therapeutic management and novel therapies (including not only RNAi, but also other therapeutic perspectives). The specific opinions of both adult and paediatric nephrologists will be compared and the ethical issues, as well as challenges faced by physicians and patients in developing countries, will also be discussed. Despite all the accomplishments, there are still looming questions that require further investigation and discovery.

Keywords: hyperoxaluria, nephrocalcinosis, nephrolithiasis, oxalate, RNAi
primary hyperoxaluria was first described in 1969 [3], well before the demonstration that PH1 was a peroxisomal disease due to decreased activity of the peroxisomal alanine-glyoxylate aminotransferase in hepatocytes from two patients, as compared with five healthy controls [4]. Even before this pathophysiological explanation, some authors had already proposed combined kidney/liver transplantation in PH1, unfortunately with a fatality from generalized cytomegalovirus infection in the first patient [5]. Later on, pre-emptive liver transplantation and liver cell transplantation were proposed [6, 7]. The murine model of PH1 was described in 1999 [8], and in 2006 adenoviral gene therapy was proven to be effective in this model [9]. In parallel, scientific networks and patients’ associations emerged, on both sides of the Atlantic Ocean, with the Oxalosis and Hyperoxaluria Foundation (OHF) in the USA and OxalEurope in Europe. This led to the development of clinical registries, which dramatically improved our knowledge of epidemiology and clinical course of the disease, notably by dissecting the clinical course of not only PH1 but also the other two subtypes currently known, PH2 and PH3 [10–13]. Clinical guidelines have also been proposed to guide the diagnosis and management of PH1 patients [14], and these are being currently updated to incorporate utilization of some of the recently introduced novel therapies.

Before 2020, management of patients with PH1 consisted of intensive hydration, urine alkalinization and CKD management [15], and vitamin B6 in patients with specific mistargeting gene mutations [2, 14, 15]. Among patients who reach ESKD, intensive daily haemodialysis should be performed before proceeding to combined or sequential liver/kidney transplantation [1, 14]. Patients undergoing transplantation are at risk of not only severe perioperative complications, but also the long-term consequences of immunosuppression. Novel therapies based on RNA interference (RNAi) of glycolate oxidase (GO) (lumasiran) and lactate dehydrogenase A (nedosiran) have recently emerged and aimed at attenuating hepatic oxalate synthesis in PH1 [16, 17]. Lumasiran was approved in 2020 by both the EMA and the FDA [18], and nedosiran is currently being evaluated for FDA approval. These therapies are a real game changer for managing those with PH1, likely improving quality of life and potentially preventing the need for transplantation.

This supplement of Clinical Kidney Journal includes contemporary reviews of the pathophysiology and genetics, (conventional) medical therapeutic management, urological therapeutic management and novel therapies (including not only RNAi, but also other therapeutic perspectives). The specific opinions of both adult and paediatric nephrologists will be compared and the ethical issues, as well as challenges faced by physicians and patients in developing countries, will also be discussed.

Despite all the accomplishments, there are still looming questions that require further investigation and discovery. Answering these questions should pave the way for better treatment of patients afflicted with PH1, PH2, PH3 and perhaps other yet to be identified subtypes.

FUNDING

This article was published as part of a supplement made possible by Alnylam Pharmaceuticals, Inc. Alnylam selected the Guest Editors for the supplement and agreed the educational objectives with them. The Guest Editors were solely responsible for determining the manuscript topics and the author selection.

CONFLICT OF INTEREST STATEMENT

J.B. has received consulting and speaking fees from Alnylam and consulting fees from Dicerna and Biocodex. K.D.W. has received consulting fees from Alnylam and is on the advisory board for Alnylam.

REFERENCES

1. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013; 369: 649–658
2. Harambat J, Fargue S, Acquaviva C et al. Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 2010; 77: 443–449
3. Gibbs DA, Watts RW. The action of pyridoxine in primary hyperoxaluria. Clin Sci 1969; 37: 565
4. Danpure CJ, Jennings PR. Peroxisomal alanine-glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 1986; 201: 20–24
5. Watts RW, Calne RY, Williams R et al. Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation. Q J Med 1985; 57: 697–703
6. Cochat P, Faure JL, Divry P et al. Liver transplantation in primary hyperoxaluria type 1. Lancet 1989; 1: 1142–1143
7. Beck BB, Habbig S, Dittrich K et al. Liver cell transplantation in severe infantile oxalosis—a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 2012; 27: 2984–2989
8. Li XM, Salido EC, Shapiro LJ. The mouse alanine:glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 2006; 103: 18249–18254
9. Salido EC, Li XM, Lu Y et al. Alkaline-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 2006; 103: 18249–18254
10. Zhao F, Bergstralh EJ, Mehta RA et al. Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 2016; 11: 119–126
11. Mandrile G, van Woerden CS, Berchialla P et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 2014; 86: 1197–1204
12. Garrelfs SF, Rumsby G, Peters-Sengers H et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 2019; 96: 1389–1399
13. Martin-Higueras C, Garrelfs SF, Groothoff JW et al. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 2021; 100: 621–635
14. Cochat P, Hulton S-A, Acquaviva C et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012; 27: 1729–1736
15. Fargue S, Harambat J, Gagnadoux M-F et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009; 76: 767–773
16. Garrelfs SF, Frishberg Y, Hulton SA et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 2021; 384: 1216–1226
17. Hoppe B, Koch A, Cochat P et al. Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria. Kidney Int 2021; S0085-2538(21)00807-3
18. Scott LJ, Keam SJ. Lumasiran: first approval. Drugs 2021; 81: 277–282